Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7820 | 1.00 | — | — | |
| Hydrogen Peroxide SCHEMBL7056368 | 0.94 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| SCHEMBL1499953 | 0.94 | — | — | |
| SCHEMBL11681547 | 0.94 | — | — | |
| SCHEMBL3959241 | 0.94 | — | — | |
| SCHEMBL10527922 | 0.94 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| Hydrogen Sulfide SCHEMBL8062675 | 0.94 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| SCHEMBL15467677 | 0.94 | — | — | |
| SCHEMBL21044698 | 0.94 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| SCHEMBL8859381 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137543-A1 | ADVANCED RNA TARGETING (ARNATAR) | ARNATAR THERAPEUTICS, INC (US) | 2024-06-27 | — | — | WO | disclosed |
| US-11866780-B2 | Nucleic acid sample enrichment for sequencing applications | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-10577646-B2 | Nucleotide analogs | ABBOTT MOLECULAR INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180320219-A1 | NUCLEOTIDE ANALOGS | ABBOTT MOLECULAR INC. | 2018-11-08 | — | — | US | disclosed |
| US-20170298431-A1 | NUCLEIC ACID SAMPLE ENRICHMENT FOR SEQUENCING APPLICATIONS | Ilumina Cambridge Limited (GB) | 2017-10-19 | — | — | US | disclosed |
| EP-2958429-A2 | COMPOSITIONS AND METHODS TO INACTIVATE AND/OR REDUCE PRODUCTION OF MICROBIAL TOXINS | BIOLOG, INC. (US) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014130655-A2 | COMPOSITIONS AND METHODS TO INACTIVATE AND/OR REDUCE PRODUCTION OF MICROBIAL TOXINS | BIOLOG, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| EP-2665359-A1 | CROP PLANT-COMPATIBLE HERBICIDAL COMPOSITIONS CONTAINING HERBICIDES AND SAFENERS | Rotam Agrochem International Co., Ltd (CN) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012097629-A1 | CROP PLANT-COMPATIBLE HERBICIDAL COMPOSITIONS CONTAINING HERBICIDES AND SAFENERS | ROTAM AGROCHEM INTERNATIONAL CO., LTD (CN) | 2012-07-26 | — | — | WO | disclosed |
| WO-2011105901-A2 | ANTAGONISTS OF COMPLEMENT COMPONENT 9 (C9) AND USES THEREOF | ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011105900-A2 | ANTAGONISTS OF COMPLEMENT COMPONENT 8-ALPHA (C8-ALPHA) AND USES THEREOF | ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2011-09-01 | — | — | WO | disclosed |
| US-20050142581-A1 | Microrna as ligands and target molecules | ISIS PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2005023986-A2 | MICRORNA AS LIGANDS AND TARGET MOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-5922654-A | TWO OR MORE ORGANOMETALLIC COMPOUNDS WHERE THE METAL IS A TRANSITION METAL OR SEMIMETAL, OR ZINC; FOR EXAMPLE, ZINC DIALKYLDITHIOPHOSPHATE, OR NICKEL DIALKYLDITHIOCARBAMATE; HIGHER LOAD BEARING PROPERTIES, HIGH TEMPERATURE PERFORMANCE | NSK LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| US-5506212-A | HYBRIDIZE TO DNA AND RNA SEQUENCES; INCREASED STABILITY | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577646-B2 | Nucleotide analogs | NUDT1, NT5C3B, RNGTT | CA2 4339/4885SLC34A1 723/4885KDM4E 4150/4885 |
| US-20180320219-A1 | NUCLEOTIDE ANALOGS | NUDT1, NT5C3B, RNGTT | CA2 4339/4885SLC34A1 723/4885KDM4E 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.